BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) investors cheer the news that the FDA has approved the supplemental New Drug Application (sNDA) to expand the indication …
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) investors have a smile on their faces Thursday morning, after the drug maker announced results from a second interim …
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) shares slipped yesterday 9% after the drug discovery company reported first-quarter results and update on its clinical progress.
The volatile biotech sector did not fail to live up to its reputation this week. Analysts weigh in on Cerus Corporation (NASDAQ:CERS) as …
Oppenheimer analysts express mixed sentiments on Sarepta Therapeutics, Inc. (NASDAQ:SRPT) and BioCryst Pharmaceuticals (NASDAQ:BCRX) as one company awaits an extended review from the FDA …
Piper Jaffray’s healthcare analyst Charles Duncan is weighing in today on biotech companies CTI BioPharma Corp (NASDAQ:CTIC) and BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX), as shares …
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) announced results from OPuS-2 (Oral ProphylaxiS-2), a clinical trial of avoralstat administered three times daily as a liquid-filled soft …
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) announced financial results for the second quarter ended June 30, 2015.
